SCHEMBL6780965

SCHEMBL6780965

CC(C)Oc1ccc(N(C)C(=O)COCc2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.45
LMNA P02545 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MLYCD O95822 2/20 0.43
MAOB P27338 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ALOX5 P09917 1/20 0.42
MCL1 Q07820 1/20 0.42
FAAH O00519 1/20 0.41
POLB P06746 1/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
NOX1 Q9Y5S8 1/20 0.41
ALPL P05186 1/20 0.41
ALPI P09923 1/20 0.41
ALPG P10696 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22312249 0.85 KMT2A (0.52) NPC1KMT2AKDM4EALDH1A1MEN1
SCHEMBL1019064 0.81 PPIB (0.52) L3MBTL1MLYCDMAOBRAB9AKMT2A
SCHEMBL6785142 0.81 PLA2G4B (0.50) MLYCDNPC1RAB9AALOX5POLB
SCHEMBL1016035 0.77 ALDH1A1 (0.52) LMNAL3MBTL1NPC1RAB9AKMT2A
SCHEMBL19261529 0.75 TSHR (0.58) CNR2LMNAL3MBTL1NPC1RAB9A
SCHEMBL21480025 0.74 NPC1 (0.46) LMNANPC1RAB9AKMT2AALDH1A1
SCHEMBL2290221 0.74 SMN1; SMN2 (0.51) L3MBTL1NPC1RAB9AALOX5KMT2A
SCHEMBL6789881 0.73 FAAH (0.51) FAAHPOLBKMT2AALDH1A1PKM
SCHEMBL22073096 0.72 ALDH1A1 (0.44) L3MBTL1NPC1RAB9AKMT2AKDM4E
SCHEMBL8387473 0.71 ALOX5 (0.74) MAOBALOX5NOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6710060-B2 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2004-03-23 US disclosed
US-6642257-B2 Fewer side-effects than do the conventional analgesics; 4-hydroxypiperidine derivatives MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2003-11-04 US disclosed
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-12-12 US disclosed
US-20020049229-A1 Agents for treating neuropathic pain MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-04-25 US disclosed
EP-1182193-A1 REMEDIES FOR NEUROPATHIC PAIN MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-02-27 EP disclosed
EP-1182192-A1 4-HYDROXYPIPERIDINE DERIVATIVES HAVING ANTIARRHYTHMIC EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-02-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049229-A1 Agents for treating neuropathic pain OPRM1, OPRK1, OPRL1 CNR2 8/4885LMNA 4829/4885L3MBTL1 3004/4885
US-20020188006-A1 4-hydroxypiperidine derivatives having antiarrhythmic activity SCN5A, RYR2, SCN1B CNR2 1258/4885LMNA 337/4885L3MBTL1 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.